Katie Rose Ryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katie Rose Ryan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Brendan Frett
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, United States
3 shared publications Noemi Garcia Garcia
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences
3 shared publicationsBaku Acharya
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
2 shared publicationsDebasmita Saha
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
2 shared publicationsErica Lane Smith
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
2 shared publicationsNaga Rajiv Lakkaniga
Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
2 shared publications
Latest Publications
- Open Access
- 24 February 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (5) , e202503494
Rnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulation
Rnd3 regulates cellular processes commonly dysregulated in cancer, and altered Rnd3 expression has been linked to several cancer types. Here, we show lung adenocarcinoma patients expressing low levels of Rnd3 have significantly higher survival rates. To gain mechanistic insight into this correlation, we knocked down Rnd3 in lung adenocarcinoma A549 and H460 cell lines and patient-derived lung-to-brain metastasis (PDLBM) cell lines as a proxy for advanced disease. Depletion of Rnd3 expression decreases cell invasion and migration, two hallmarks of metastasis, independently of RhoA-ROCK1 signaling in both lung adenocarcinoma and PDLBM cell lines, indicating the involvement of a novel pathway. The expression of alpha 5 integrin was increased in Rnd3-depleted A549 cells, and knocking down alpha 5 integrin restored cell migration and invasion rates in A549 cells. Identification of a RhoA-ROCK1-independent mechanism by which Rnd3 modulates alpha 5 integrin expression to control cell migration and invasion provides new insights into the molecular basis of pro-malignant properties. These properties that drive the metastatic potential of lung adenocarcinoma may be exploited to target metastatic disease.
- 24 February 2026
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 9 (5) , e202503494
Open AccessRnd3 regulates lung cancer cell invasion and migration independently of ROCK1 signaling via alpha 5 integrin modulation
Rnd3 regulates cellular processes commonly dysregulated in cancer, and altered Rnd3 expression has been linked to several cancer types. Here, we show lung adenocarcinoma patients expressing low levels of Rnd3 have significantly higher survival rates. To gain mechanistic insight into this correlation, we knocked down Rnd3 in lung adenocarcinoma A549 and H460 cell lines and patient-derived lung-to-brain metastasis (PDLBM) cell lines as a proxy for advanced disease. Depletion of Rnd3 expression decreases cell invasion and migration, two hallmarks of metastasis, independently of RhoA-ROCK1 signaling in both lung adenocarcinoma and PDLBM cell lines, indicating the involvement of a novel pathway. The expression of alpha 5 integrin was increased in Rnd3-depleted A549 cells, and knocking down alpha 5 integrin restored cell migration and invasion rates in A549 cells. Identification of a RhoA-ROCK1-independent mechanism by which Rnd3 modulates alpha 5 integrin expression to control cell migration and invasion provides new insights into the molecular basis of pro-malignant properties. These properties that drive the metastatic potential of lung adenocarcinoma may be exploited to target metastatic disease.
- 9 May 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 106, 117749
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- 9 May 2024
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 106, 117749
Discovery of 9H-pyrimido[4,5-b]indole derivatives as dual RET/TRKA inhibitors
- 17 August 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (16) , 11747-11773
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
Rearranged during transfection (RET) is a receptor tyrosine kinase essential for the normal development and maturation of a diverse range of tissues. Aberrant RET signaling in cancers, due to RET mutations, gene fusions, and overexpression, results in the activation of downstream pathways promoting survival, growth, and metastasis. Pharmacological manipulation of RET is effective in treating RET-driven cancers, and efforts toward developing RET-specific therapies have increased over the last 5 years. In 2020, RET-selective inhibitors pralsetinib and selpercatinib achieved clinical approval, which marked the first approvals for kinase inhibitors specifically developed to target the RET oncoprotein. This Perspective discusses current development and clinical applications for RET precision medicine by providing an overview of the incremental improvement of kinase inhibitors for use in RET-driven malignancies.
- 17 August 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 64 (16) , 11747-11773
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development
Rearranged during transfection (RET) is a receptor tyrosine kinase essential for the normal development and maturation of a diverse range of tissues. Aberrant RET signaling in cancers, due to RET mutations, gene fusions, and overexpression, results in the activation of downstream pathways promoting survival, growth, and metastasis. Pharmacological manipulation of RET is effective in treating RET-driven cancers, and efforts toward developing RET-specific therapies have increased over the last 5 years. In 2020, RET-selective inhibitors pralsetinib and selpercatinib achieved clinical approval, which marked the first approvals for kinase inhibitors specifically developed to target the RET oncoprotein. This Perspective discusses current development and clinical applications for RET precision medicine by providing an overview of the incremental improvement of kinase inhibitors for use in RET-driven malignancies.
- 8 February 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (10) , 1605-1608
Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
A fragment‐based drug‐discovery approach was used on a pyrazoloadenine fragment library to uncover new molecules that target the RET (REarranged during Transfection) oncoprotein, which is a driver oncoprotein in ∼2 % of non‐small‐cell lung cancers. The fragment library was screened against the RET kinase and LC‐2/ad (RET‐driven), KM‐12 (TRKA‐driven matched control) and A549 (cytotoxic control) cells to identify selective scaffolds that could inhibit RET‐driven growth. An unsubstituted pyrazoloadenine fragment was found to be active on RET in a biochemical assay, but reduced cell viability in non‐RET‐driven cell lines (EC50=1 and 3 μM, respectively). To increase selectivity for RET, the pyrazoloadenine was modeled in the RET active site, and two domains were identified that were probed with pyrazoloadenine fragment derivatives to improve RET affinity. Scaffolds at each domain were merged to generate a novel lead compound, 8 p, which exhibited improved activity and selectivity for the RET oncoprotein (A549 EC50=5.92 μM, LC‐2/ad EC50=0.016 μM, RET IC50=0.000326 μM).
- 8 February 2021
- Published by Wiley in ChemMedChem
- Vol. 16 (10) , 1605-1608
Pyrazoloadenine Inhibitors of the RET Lung Cancer Oncoprotein Discovered by a Fragment Optimization Approach
A fragment‐based drug‐discovery approach was used on a pyrazoloadenine fragment library to uncover new molecules that target the RET (REarranged during Transfection) oncoprotein, which is a driver oncoprotein in ∼2 % of non‐small‐cell lung cancers. The fragment library was screened against the RET kinase and LC‐2/ad (RET‐driven), KM‐12 (TRKA‐driven matched control) and A549 (cytotoxic control) cells to identify selective scaffolds that could inhibit RET‐driven growth. An unsubstituted pyrazoloadenine fragment was found to be active on RET in a biochemical assay, but reduced cell viability in non‐RET‐driven cell lines (EC50=1 and 3 μM, respectively). To increase selectivity for RET, the pyrazoloadenine was modeled in the RET active site, and two domains were identified that were probed with pyrazoloadenine fragment derivatives to improve RET affinity. Scaffolds at each domain were merged to generate a novel lead compound, 8 p, which exhibited improved activity and selectivity for the RET oncoprotein (A549 EC50=5.92 μM, LC‐2/ad EC50=0.016 μM, RET IC50=0.000326 μM).
- 30 September 2020
- Published by Wiley in European Journal of Haematology
- Vol. 106 (1) , 90-99
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma
Objectives: Two promising epigenetic therapeutic targets have emerged for the treatment of hematologic malignancies, BET and CBP/EP300 proteins. Several studies have shown that targeting these individual classes of proteins has anti‐tumor activity in multiple myeloma (MM), as well as other cancers. Here, we present the first data exploring the anti‐tumor activity of two novel dual inhibitors, NEO2734 and NEO1132, of both BET and CBP/EP300 proteins in MM.Methods: Sixteen MM cell lines (MMCLs) were treated with the dual inhibitors NEO2734 and NEO1132, the single BET inhibitors JQ1, OTX015, IBET‐762, and IBET‐151, and a single CBP/EP300 inhibitor CPI‐637.Results: The dual inhibitor NEO2734 showed strong anti‐tumor activity and was consistently highly active against all MMCLs, being as potent as JQ1 and more so than other single inhibitors. NEO2734 and NEO11132 induced a significant G1 cell cycle arrest and decreased c‐MYC and IRF4 protein levels in MMCLs compared to the other single inhibitors. Sensitivity to the dual inhibitors was not dependent on a specific MM molecular subgroup but correlated with c‐MYC protein expression levels.Conclusions: The dual inhibition of BET and CBP/EP300 has potential therapeutic benefits for patients with MM.
- 30 September 2020
- Published by Wiley in European Journal of Haematology
- Vol. 106 (1) , 90-99
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma
Objectives: Two promising epigenetic therapeutic targets have emerged for the treatment of hematologic malignancies, BET and CBP/EP300 proteins. Several studies have shown that targeting these individual classes of proteins has anti‐tumor activity in multiple myeloma (MM), as well as other cancers. Here, we present the first data exploring the anti‐tumor activity of two novel dual inhibitors, NEO2734 and NEO1132, of both BET and CBP/EP300 proteins in MM.Methods: Sixteen MM cell lines (MMCLs) were treated with the dual inhibitors NEO2734 and NEO1132, the single BET inhibitors JQ1, OTX015, IBET‐762, and IBET‐151, and a single CBP/EP300 inhibitor CPI‐637.Results: The dual inhibitor NEO2734 showed strong anti‐tumor activity and was consistently highly active against all MMCLs, being as potent as JQ1 and more so than other single inhibitors. NEO2734 and NEO11132 induced a significant G1 cell cycle arrest and decreased c‐MYC and IRF4 protein levels in MMCLs compared to the other single inhibitors. Sensitivity to the dual inhibitors was not dependent on a specific MM molecular subgroup but correlated with c‐MYC protein expression levels.Conclusions: The dual inhibition of BET and CBP/EP300 has potential therapeutic benefits for patients with MM.
- Open Access
Microhomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma
MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We show that MYC rearrangements are present in 36.0% of newly diagnosed myeloma patients, as detected in the largest set of next generation sequencing data to date (n=1267). Rearrangements were complex and associated with increased expression of MYC and PVT1 , but not other genes at 8q24. The highest effect on gene expression was detected in cases where the MYC locus is juxtaposed next to super-enhancers associated with genes such as IGH , IGK , IGL , TXNDC5 / BMP6 , FAM46C and FOXO3 . We identified three hotspots of recombination at 8q24, one of which is enriched for IGH-MYC translocations. Breakpoint analysis indicates primary myeloma rearrangements involving the IGH locus occur through non-homologous end joining, whereas secondary MYC rearrangements occur through microhomology-mediated end joining. This mechanism is different to lymphomas, where non-homologous end joining generates MYC rearrangements. Rearrangements resulted in over-expression of key genes and ChIP-seq identified that HK2 , a member of the glucose metabolism pathway, is directly over-expressed through binding of MYC at its promoter.
Open AccessMicrohomology-mediated end joining drives complex rearrangements and over-expression of MYC and PVT1 in multiple myeloma
MYC is a widely acting transcription factor and its deregulation is a crucial event in many human cancers. MYC is important biologically and clinically in multiple myeloma, but the mechanisms underlying its dysregulation are poorly understood. We show that MYC rearrangements are present in 36.0% of newly diagnosed myeloma patients, as detected in the largest set of next generation sequencing data to date (n=1267). Rearrangements were complex and associated with increased expression of MYC and PVT1 , but not other genes at 8q24. The highest effect on gene expression was detected in cases where the MYC locus is juxtaposed next to super-enhancers associated with genes such as IGH , IGK , IGL , TXNDC5 / BMP6 , FAM46C and FOXO3 . We identified three hotspots of recombination at 8q24, one of which is enriched for IGH-MYC translocations. Breakpoint analysis indicates primary myeloma rearrangements involving the IGH locus occur through non-homologous end joining, whereas secondary MYC rearrangements occur through microhomology-mediated end joining. This mechanism is different to lymphomas, where non-homologous end joining generates MYC rearrangements. Rearrangements resulted in over-expression of key genes and ChIP-seq identified that HK2 , a member of the glucose metabolism pathway, is directly over-expressed through binding of MYC at its promoter.
- Open Access
- 21 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0204057
Activation of RHO-1 in cholinergic motor neurons competes with dopamine signalling to control locomotion
The small GTPase RhoA plays a crucial role in the regulation of neuronal signalling to generate behaviour. In the developing nervous system RhoA is known to regulate the actin cytoskeleton, however the effectors of RhoA-signalling in adult neurons remain largely unidentified. We have previously shown that activation of the RhoA ortholog (RHO-1) in C. elegans cholinergic motor neurons triggers hyperactivity of these neurons and loopy locomotion with exaggerated body bends. This is achieved in part through increased diacylglycerol (DAG) levels and the recruitment of the synaptic vesicle protein UNC-13 to synaptic release sites, however other pathways remain to be identified. Dopamine, which is negatively regulated by the dopamine re-uptake transporter (DAT), has a central role in modulating locomotion in both humans and C. elegans. In this study we identify a new pathway in which RHO-1 regulates locomotory behaviour by repressing dopamine signalling, via DAT-1, linking these two pathways together. We observed an upregulation of dat-1 expression when RHO-1 is activated and show that loss of DAT-1 inhibits the loopy locomotion phenotype caused by RHO-1 activation. Reducing dopamine signalling in dat-1 mutants through mutations in genes involved in dopamine synthesis or in the dopamine receptor DOP-1 restores the ability of RHO-1 to trigger loopy locomotion in dat-1 mutants. Taken together, we show that negative regulation of dopamine signalling via DAT-1 is necessary for the neuronal RHO-1 pathway to regulate locomotion.
- 21 September 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0204057
Open AccessActivation of RHO-1 in cholinergic motor neurons competes with dopamine signalling to control locomotion
The small GTPase RhoA plays a crucial role in the regulation of neuronal signalling to generate behaviour. In the developing nervous system RhoA is known to regulate the actin cytoskeleton, however the effectors of RhoA-signalling in adult neurons remain largely unidentified. We have previously shown that activation of the RhoA ortholog (RHO-1) in C. elegans cholinergic motor neurons triggers hyperactivity of these neurons and loopy locomotion with exaggerated body bends. This is achieved in part through increased diacylglycerol (DAG) levels and the recruitment of the synaptic vesicle protein UNC-13 to synaptic release sites, however other pathways remain to be identified. Dopamine, which is negatively regulated by the dopamine re-uptake transporter (DAT), has a central role in modulating locomotion in both humans and C. elegans. In this study we identify a new pathway in which RHO-1 regulates locomotory behaviour by repressing dopamine signalling, via DAT-1, linking these two pathways together. We observed an upregulation of dat-1 expression when RHO-1 is activated and show that loss of DAT-1 inhibits the loopy locomotion phenotype caused by RHO-1 activation. Reducing dopamine signalling in dat-1 mutants through mutations in genes involved in dopamine synthesis or in the dopamine receptor DOP-1 restores the ability of RHO-1 to trigger loopy locomotion in dat-1 mutants. Taken together, we show that negative regulation of dopamine signalling via DAT-1 is necessary for the neuronal RHO-1 pathway to regulate locomotion.